Associated Papers
Current opinions on Noonan syndrome and RASopathies.
Weaver KN et al.
Current Opinion in Pediatrics, 2026
Discriminating activating, deactivating and resistance variants in protein kinases.
Singh G et al.
Genome Medicine, 2025
PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P.
Janku F et al.
Jco Precision Oncology, 2025
Small Molecule B-RAF Inhibitors as Anti-Cancer Therapeutics: Advances in Discovery, Development, and Mechanistic Insights.
Anaya YA et al.
International Journal of Molecular Sciences, 2025
BRAF V600E in cancer: Exploring structural complexities, mutation profiles, and pathway dysregulation.
Bharti J et al.
Experimental Cell Research, 2025
Genomic Landscapes of Early-Onset Versus Average-Onset Colorectal Cancer Populations.
Storandt MH et al.
Cancers, 2025
BRAF mutant appendiceal adenocarcinoma differs from colorectal cancer but responds to BRAF-targeted therapy.
Pattalachinti VK et al.
Npj Precision Oncology, 2025
Oncogenic non-V600 mutations evade the regulatory machinery of RAF including the Cdc37/Hsp90 chaperone and the 14-3-3 scaffold.
Wan X et al.
Theranostics, 2025
VarMeter2: An enhanced structure-based method for predicting pathogenic missense variants through Mahalanobis distance.
Ohno S et al.
Computational and Structural Biotechnology Journal, 2025
Genetic aetiologies in relation to response to the ketogenic diet in 226 children with epilepsy.
Dahlin M et al.
Brain Communications, 2025
Preclinical NCI-MPACT: prospective modeling of the mutation-based NCI-MPACT clinical trial therapeutic strategy in patient-derived xenograft models.
Evrard YA et al.
Frontiers in Oncology, 2025
Cardiofaciocutaneous syndrome and immunodeficiency: data from an international multicenter cohort.
Di Majo BE et al.
Frontiers in Immunology, 2025
Indeterminate DC histiocytosis is distinct from LCH and often associated with other hematopoietic neoplasms.
Ozkaya N et al.
Blood Advances, 2024
PD-L1 and nectin-4 expression and genomic characterization of bladder cancer with divergent differentiation.
Martini DJ et al.
Cancer, 2024
Therapeutic vulnerabilities and pan-cancer landscape of BRAF class III mutations in epithelial solid tumors.
Özgü E et al.
Bjc Reports, 2024
Features and efficacy of triple-targeted therapy for patients with EGFR-mutant non-small-cell lung cancer with acquired BRAF alterations who are resistant to epidermal growth factor receptor tyrosine kinase inhibitors.
Li Y et al.
Esmo Open, 2024
Targeting Non-V600 Mutations in BRAF: A Single Institution Retrospective Analysis and Review of the Literature.
Chaudhary HA et al.
Drugs in R&d, 2024
Mutational Landscapes of Normal Skin and Their Potential Implications in the Development of Skin Cancer: A Comprehensive Narrative Review.
Riew TR et al.
Journal of Clinical Medicine, 2024
Scalable approaches for generating, validating and incorporating data from high-throughput functional assays to improve clinical variant classification.
Padigepati SR et al.
Human Genetics, 2024
Exploring New Drug Repurposing Opportunities for MEK Inhibitors in RASopathies: A Comprehensive Review of Safety, Efficacy, and Future Perspectives of Trametinib and Selumetinib.
Gazzin A et al.
Life (basel, Switzerland), 2024
Clonal hematopoiesis is associated with cardiovascular events in patients with stable coronary artery disease.
Dregoesc MI et al.
Iscience, 2024
Targeted next-generation sequencing of 491 lung cancers in clinical practice: Implications for future detection strategy and targeted therapy.
Liu XD et al.
Heliyon, 2024
Epilepsy in cardiofaciocutaneous syndrome: Clinical burden and response to anti-seizure medication.
Kenney-Jung DL et al.
American Journal of Medical Genetics. Part A, 2024
Status epilepticus in BRAF-related cardio-facio-cutaneous syndrome: Focus on neuroimaging clues to physiopathology.
Musto E et al.
Epilepsia Open, 2024
Identification of an unusual combination of actionable mutations through genomic profiling in a child with an aggressive sarcoma.
Sherif S et al.
Pediatric Blood & Cancer, 2024
Exploring the clinical complexity of cardio-facio-cutaneous syndrome: insights from a pediatric case series.
Ou Y et al.
Frontiers in Pediatrics, 2024
Non-canonical BRAF variants and rearrangements in hairy cell leukemia.
Langabeer SE
Oncology Research, 2024
Diagnostic efficiency of exome-based sequencing in pediatric patients with epilepsy.
Zou H et al.
Frontiers in Genetics, 2024
BRAF mutations and concurrent alterations in patients with soft tissue sarcoma.
Kobayashi H et al.
Genes, Chromosomes & Cancer, 2023
Systematic ophthalmologic evaluation in cardio-facio-cutaneous syndrome: A genotype-endophenotype correlation.
Crincoli E et al.
American Journal of Medical Genetics. Part A, 2023
Treatment of Refractory Epilepsy With MEK Inhibitor in Patients With RASopathy.
D'Onofrio G et al.
Pediatric Neurology, 2023
Unique Spectrum of Activating BRAF Alterations in Prostate Cancer.
Chehrazi-Raffle A et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2023
Circulating Tumor DNA: A Promising Biomarker for Predicting Recurrence in Patients with BRAF-Negative Melanoma.
Aoude LG et al.
The Journal of Molecular Diagnostics : Jmd, 2023
Hairy cell leukaemia with unusual BRAF mutations.
Maitre E et al.
Journal of Cellular and Molecular Medicine, 2023
BRAFΔβ3-αC in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability.
Lauinger M et al.
Science Advances, 2023
Protein Tyrosine Phosphatase Non-Receptor 11 (PTPN11/Shp2) as a Driver Oncogene and a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC).
Richards CE et al.
International Journal of Molecular Sciences, 2023
Molecular profiling of colorectal cancer in a genetically admixed Hispanic population.
Montes-Rodríguez IM et al.
Cancer Medicine, 2023
KRAS, NRAS, BRAF, HER2 and MSI Status in a Large Consecutive Series of Colorectal Carcinomas.
Martianov AS et al.
International Journal of Molecular Sciences, 2023
BRAF mutation in neuroblastoma: A rare finding.
Hutchins SC et al.
Pediatric Blood & Cancer, 2023
Molecular profiling of solid tumors by next-generation sequencing: an experience from a clinical laboratory.
Bhai P et al.
Frontiers in Oncology, 2023
Infantile epileptic spasms syndrome in children with cardiofaciocutanous syndrome: Clinical presentation and associations with genotype.
Kenney-Jung DL et al.
American Journal of Medical Genetics. Part C, Seminars in Medical Genetics, 2022
Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group.
Vranic S et al.
Acta Medica Academica, 2022
Ongoing progress in BRAF-mutated non-small cell lung cancer.
Abdayem P et al.
Clinical Advances in Hematology & Oncology : H&o, 2022
NGS-Based Molecular Karyotyping of Multiple Myeloma: Results from the GEM12 Clinical Trial.
Rosa-Rosa JM et al.
Cancers, 2022